Your search for major depressive disorder returned 60 results

Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.

Researchers assessed characteristics and correlates of metabolic syndrome in adolescents with major depressive disorder or bipolar disorder depression.

Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.

The researchers sought to examine whether inflammation and white matter microstructure play a role in treatment response in major depressive disorder.

Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.

For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.

Investigators searched publication databases for randomized controlled trials evaluating cognitive training and remediation interventions among patients with MDD.

Outpatients were recruited at the Instituto Nacional de Psiquiatía (National Institute of Psychiatry) in Mexico and were evaluated for alcohol dependence and major depressive disorder.

Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.

Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.

Investigators sourced data for this study from the Stockholm Major Depressive Disorder Cohort. Between 2010 and 2018, all patients in the Stockholm region who met the criteria for MDD were enrolled in the cohort.

This prospective, multi-center, open-label trial, CAN-BIND-1 was conducted between 2012 and 2017.

In this review, authors focused on the psychiatric issues that often accompany migraine and the effects of botulinum toxin A on migraine.

This retrospective cohort study evaluated patient data from patients aged 50 years or older who received an acute course of ECT between 2011 and 2019 and were evaluated for cognition and depression outcomes on the basis of baseline cognitive function.

Data for this study were sourced from 4 active treatment arms of 4 randomized, controlled trials conducted by the National Institutes of Health in the United States between 2006 and 2018.

Previous studies have found that perinatal women have had detriments to sleep and depression during the pandemic; however, all studies to date in the perinatal setting have lacked a comparator group, so robust conclusions about the effect of the COVID-19 pandemic have not been elucidated.

Patients who had treatment-naïve MDD were recruited in the US between 2007 and 2013 for the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study.

A cross-sectional family study sought to determine if parents’ transmission of anxiety is sex specific.

Patients with MDD were randomly assigned in a 1:1:1 ratio to receive 1.5 mg daily cariprazine, 3.0 mg daily cariprazine, or placebo for 6 weeks.

A study was conducted to determine the effects of switching or augmenting antidepressant therapy in adults with treatment-resistant depression.

Investigators looked into which treatment fared better for patients with anxiety disorders: a mindfulness-based stress reduction intervention or escitalopram.

A placebo-controlled study of smokers with MDD evaluated varenicline with vs without behavioral interventions for smoking cessation.

In a case-control study, researchers assessed the potential link between late-onset depression and the risk of developing major cognitive disorder.

The REAL-ESK study was an observational, retrospective, multicenter study conducted in Italy.

For this study, patients with generalized anxiety disorder were recruited from the Nanfang Hospital in China between 2018 and 2020.

The Alpha-Stim-D trial was a noncommercial, multicenter, randomly assigned, parallel group, double-blind trial conducted at 25 primary care practices in the United Kingdom.

Children and adolescents were evaluated for receipt of antipsychotics between 2000 and 2019 in England.

This observational study was conducted by telephone interviews between April and July 2020.

In this study, participants underwent cardiorespiratory fitness (CRF) testing using the 6-minute walk test and perceived CRF was evaluated by asking participants what they thought their current aerobic fitness level was.

Researchers examined associations between polygenic risk scores and neuropsychiatric conditions using data from phenome-wide association studies.